AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36894736 — intervention group
Group type: COMPARATOR
Intervention: No-Stress condition (n = 24)
Number of subjects: 48
Study 36894736 — intervention group
Group type: EXPERIMENTAL
Intervention: Women using oral contraceptives (n = 9 in Stress, n = 10 in No-Stress)
Number of subjects: 48
Study 33660906 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Cognitive‐Affective Therapy
Number of subjects: 112
Study 33660906 — intervention group
Group type: COMPARATOR
Intervention: Cognitive‐behavioural therapy administered using guided self‐help
Number of subjects: 112
Study 32989046 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic airway device for surfactant administration
Number of subjects: 350
Study 32989046 — intervention group
Group type: COMPARATOR
Intervention: Surfactant administration via endotracheal tube
Number of subjects: 350
Study 32989046 — intervention group
Group type: COMPARATOR
Intervention: Continued CPAP
Number of subjects: 350
Study 34749699 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen therapy (HFNC)
Number of subjects: 10
Study 34749699 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy (SOT)
Number of subjects: 10
Study 32397980 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrrh (500 mg capsules, three times a day for 2 weeks)
Number of subjects: 80
Study 32397980 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three times a day for 2 weeks)
Number of subjects: 80
Study 35182247 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (360 mg every 3 weeks) plus ipilimumab (1 mg/kg every 6 weeks) combined with chemotherapy (2 cycles, every 3 weeks)
Number of subjects: 58
Study 35182247 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab combined with chemotherapy
Number of subjects: 58
Study 35182247 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 58
Study 34328501 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-delivered cognitive behavioral therapy
Number of subjects: 152
Study 34328501 — intervention group
Group type: COMPARATOR
Intervention: In-person cognitive behavioral therapy
Number of subjects: 152
Study 34328501 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care group (internet-delivered therapy followed by in-person for nonresponders)
Number of subjects: 152
Study 34328501 — intervention group
Group type: COMPARATOR
Intervention: In-person cognitive behavioral therapy alone
Number of subjects: 152
Study 35587212 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow weaning
Number of subjects: 113
Study 35587212 — intervention group
Group type: COMPARATOR
Intervention: Direct weaning
Number of subjects: 113
Study 36210517 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency TAVI in shock group
Number of subjects: 179
Study 36210517 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency TAVI in no shock group
Number of subjects: 179
Study 36210517 — intervention group
Group type: COMPARATOR
Intervention: Elective TAVI group
Number of subjects: 179
Study 36210517 — intervention group
Group type: EXPERIMENTAL
Intervention: Critically ill groups (shock and no shock)
Number of subjects: 179
Study 33308680 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized response technique (Christofides' model)
Number of subjects: 0
Study 33308680 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian estimation
Number of subjects: 0
Study 33308680 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood estimation
Number of subjects: 0
Study 33308680 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of moment
Number of subjects: 0
Study 35090412 — intervention group
Group type: EXPERIMENTAL
Intervention: Human library intervention
Number of subjects: 45
Study 35090412 — intervention group
Group type: COMPARATOR
Intervention: Didactic teaching session
Number of subjects: 45
Study 35090412 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 45
Study 33538831 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 3569
Study 33538831 — intervention group
Group type: COMPARATOR
Intervention: cNRT
Number of subjects: 3569
Study 32921472 — intervention group
Group type: EXPERIMENTAL
Intervention: Step‐28 (8 L/d of milk from d 11 to 28 and then 4 L/d from d 29 to 63)
Number of subjects: 48
Study 32921472 — intervention group
Group type: EXPERIMENTAL
Intervention: Step‐56 (8 L/d of milk from d 11 to 56 and 4 L/d from d 57 to 63)
Number of subjects: 48
Study 32921472 — intervention group
Group type: COMPARATOR
Intervention: Control (8 L/d of milk from d 11 to 63 and abruptly weaned)
Number of subjects: 48
Study 32921472 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 48
Study 34634640 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal naloxone
Number of subjects: 126
Study 34634640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 33396852 — intervention group
Group type: EXPERIMENTAL
Intervention: College‐based Lifestyle Modification Program (College‐based LMP)
Number of subjects: 38
Study 33396852 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 38
Study 33861140 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-by-side evaluation of virtual non-contrast (VNC) and post-contrast images
Number of subjects: 83
Study 33861140 — intervention group
Group type: COMPARATOR
Intervention: Virtual non-contrast (VNC) images
Number of subjects: 83
Study 33861140 — intervention group
Group type: COMPARATOR
Intervention: Post-contrast images
Number of subjects: 83
Study 33861140 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-by-side evaluation of VNC and post-contrast images
Number of subjects: 83
Study 36154950 — intervention group
Group type: EXPERIMENTAL
Intervention: High power condition
Number of subjects: 0
Study 36154950 — intervention group
Group type: COMPARATOR
Intervention: Low power condition
Number of subjects: 0
Study 33707110 — intervention group
Group type: EXPERIMENTAL
Intervention: kV CBCT image matching process by radiation therapists (RTTs) and radiation oncologists (ROs)
Number of subjects: 12
Study 33707110 — intervention group
Group type: COMPARATOR
Intervention: kV CBCT image matching process
Number of subjects: 12
Study 33707110 — intervention group
Group type: EXPERIMENTAL
Intervention: User's experience in image matching
Number of subjects: 12
Study 35675693 — intervention group
Group type: EXPERIMENTAL
Intervention: Apparent diffusion coefficient-based radiomic nomogram
Number of subjects: 174
Study 35675693 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical stage
Number of subjects: 174
Study 33272960 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 642
Study 33272960 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 642
Study 33272960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study 35610658 — intervention group
Group type: EXPERIMENTAL
Intervention: CBSST-Peer
Number of subjects: 252
Study 35610658 — intervention group
Group type: EXPERIMENTAL
Intervention: SST-Peer
Number of subjects: 252
Study 35610658 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 252
Study 33821935 — intervention group
Group type: EXPERIMENTAL
Intervention: TransFORM Body Treatment (TFB)
Number of subjects: 0
Study 33821935 — intervention group
Group type: COMPARATOR
Intervention: Bland moisturizer
Number of subjects: 0
Study 35654374 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenic variants in BRCA1
Number of subjects: 871
Study 35654374 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenic variants in BRCA2
Number of subjects: 871
Study 35654374 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenic variants in PALB2
Number of subjects: 871
Study 35654374 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenic variants in moderate-risk genes (ATM, BARD1, CHEK2, RAD51C, RAD52D)
Number of subjects: 871
Study 35654374 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime risk for BRCA1 mutation carriers
Number of subjects: 871
Study 35654374 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime risk for BRCA2 mutation carriers
Number of subjects: 871
Study 35654374 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime risk for PALB2 mutation carriers
Number of subjects: 871
Study 35654374 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime risk for moderate-risk gene carriers
Number of subjects: 871
Study 34479631 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued treatment
Number of subjects: 278
Study 34479631 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced or interrupted treatment
Number of subjects: 278
Study 34479631 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopped treatment completely
Number of subjects: 278
Study 34479631 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of treatment
Number of subjects: 278
Study 34479631 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for stopping treatment
Number of subjects: 278
Study 32453368 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication reduction (removal of 1 drug), n=282
Number of subjects: 569
Study 32453368 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no medication changes), n=287
Number of subjects: 569
Study 36158122 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Renal Replacement Therapy (CRRT)
Number of subjects: 66
Study 36158122 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 66
Study 33638926 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% ITR plus HA
Number of subjects: 92
Study 33638926 — intervention group
Group type: COMPARATOR
Intervention: 0.15% ITR
Number of subjects: 92
Study 32690011 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm 1 (Dutch tariff)
Number of subjects: 0
Study 32690011 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm 2 (Dutch tariff)
Number of subjects: 0
Study 32690011 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm 3 (Dutch tariff)
Number of subjects: 0
Study 32690011 — intervention group
Group type: COMPARATOR
Intervention: Observed utility (Dutch tariff)
Number of subjects: 0
Study 32690011 — intervention group
Group type: COMPARATOR
Intervention: Observed utility (U.K. tariff)
Number of subjects: 0
Study 32690011 — intervention group
Group type: COMPARATOR
Intervention: Existing algorithms
Number of subjects: 0
Study 32690011 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred newly developed algorithm
Number of subjects: 0
Study 33060043 — intervention group
Group type: EXPERIMENTAL
Intervention: HXT+VitE
Number of subjects: 0
Study 33060043 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 0
Study 33126873 — intervention group
Group type: EXPERIMENTAL
Intervention: Balancing Everyday Life (BEL)
Number of subjects: 226
Study 33126873 — intervention group
Group type: COMPARATOR
Intervention: Standard Occupational Therapy (SOT)
Number of subjects: 226
Study 36049477 — intervention group
Group type: EXPERIMENTAL
Intervention: Low weight gain group
Number of subjects: 281
Study 35369315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankura II stent graft
Number of subjects: 132
Study 35369315 — intervention group
Group type: COMPARATOR
Intervention: Ankura stent graft
Number of subjects: 132
Study 32127890 — intervention group
Group type: EXPERIMENTAL
Intervention: Target controlled infusion (TCI) of propofol with an initial target effect‐site concentration of 4mcg/ml, followed by maintenance at 2.5mcg/ml, titrated by 0.5mcg/ml as needed.
Number of subjects: 176
Study 32127890 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus of propofol, starting with an initial bolus of 1mg/kg and repeat boluses of 0.25mg/kg.
Number of subjects: 176
Study 32127890 — intervention group
Group type: EXPERIMENTAL
Intervention: Target controlled infusion (TCI) of propofol.
Number of subjects: 176
Study 32127890 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus of propofol.
Number of subjects: 176
Study 32127890 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TCI and intermittent bolus of propofol.
Number of subjects: 176
Study 34508557 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose SM03 (3600 mg, 600 mg × 6 infusions at weeks 0, 2, 4, 12, 14, and 16)
Number of subjects: 156
Study 34508557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose SM03 (2400 mg, 600 mg × 4 infusions at weeks 0, 2, 12, and 14)
Number of subjects: 156
Study 34508557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 34508557 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose SM03
Number of subjects: 156
Study 34508557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose SM03
Number of subjects: 156
Study 34508557 — intervention group
Group type: EXPERIMENTAL
Intervention: SM03 (both doses)
Number of subjects: 156
Study 34508557 — intervention group
Group type: EXPERIMENTAL
Intervention: SM03
Number of subjects: 156
Study 36470677 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib (100-150 mg twice a day for 24 weeks)
Number of subjects: 34
Study 36470677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 36470677 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Number of subjects: 34
Study 33337649 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (HF) rTMS on the left dorsolateral prefrontal cortex (DLPFC) (80 trains, 30 pulses per train, 12 s intertrain interval, 2400 pulses per session)
Number of subjects: 146
Study 33337649 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency (LF) rTMS on the right DLPFC (2 trains, 700 pulses per train, 1 s intertrain-interval, 1400 pulses per session)
Number of subjects: 146
Study 33337649 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency (LF) rTMS on the right DLPFC
Number of subjects: 146
Study 33337649 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (HF) rTMS on the left DLPFC
Number of subjects: 146
Study 35856162 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (1.3 μg/kg/hour for 24 h)
Number of subjects: 22
Study 35856162 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 22
Study 35856162 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 22
Study 34871513 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of nicorandil
Number of subjects: 90
Study 34871513 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 90
Study 35146573 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor enhancement ratio (TER)
Number of subjects: 282
Study 35146573 — intervention group
Group type: EXPERIMENTAL
Intervention: Model based on TER
Number of subjects: 282
Study 35146573 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified high-risk and non-high risk grouping based on recurrence risk score (cut-off value: 1.75)
Number of subjects: 282
Study 33967049 — intervention group
Group type: EXPERIMENTAL
Intervention: fNIRS index in non-dementia controls (NDC)
Number of subjects: 63
Study 33967049 — intervention group
Group type: EXPERIMENTAL
Intervention: fNIRS index in mild cognitive impairment (MCI) patients
Number of subjects: 63
Study 32546247 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (PN) initiated within 24 hours after PICU admission
Number of subjects: 1158
Study 32546247 — intervention group
Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition (PN) withheld for up to 1 week in the PICU
Number of subjects: 1158
Study 32546247 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 1158
Study 32546247 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' own HRQoL
Number of subjects: 1158
Study 33647343 — intervention group
Group type: COMPARATOR
Intervention: Single endoscopist (SE)
Number of subjects: 500
Study 33647343 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-assisted (NA)
Number of subjects: 500
Study 32334702 — intervention group
Group type: EXPERIMENTAL
Intervention: rfMDA
Number of subjects: 8948
Study 32334702 — intervention group
Group type: COMPARATOR
Intervention: RACD
Number of subjects: 8948
Study 32334702 — intervention group
Group type: EXPERIMENTAL
Intervention: RAVC
Number of subjects: 8948
Study 32334702 — intervention group
Group type: COMPARATOR
Intervention: No RAVC
Number of subjects: 8948
Study 32334702 — intervention group
Group type: EXPERIMENTAL
Intervention: rfMDA plus RAVC
Number of subjects: 8948
Study 32334702 — intervention group
Group type: COMPARATOR
Intervention: RACD only
Number of subjects: 8948
Study 34320822 — intervention group
Group type: EXPERIMENTAL
Intervention: MMB plus usual depression care (MMB+UDC)
Number of subjects: 389
Study 34320822 — intervention group
Group type: COMPARATOR
Intervention: Usual depression care (UDC)
Number of subjects: 389
Study 34119655 — intervention group
Group type: EXPERIMENTAL
Intervention: AngioJet-PCDT
Number of subjects: 364
Study 33963911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 56
Study 33963911 — intervention group
Group type: COMPARATOR
Intervention: Direct MT (no alteplase)
Number of subjects: 56
Study 33963911 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher eTICI scores
Number of subjects: 56
Study 33963911 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of alteplase
Number of subjects: 56
Study 33963911 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional alteplase
Number of subjects: 56
Study 36494006 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 912
Study 36494006 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice of paclitaxel, docetaxel, or vinflunine)
Number of subjects: 912
Study 36494006 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in KEYNOTE-052
Number of subjects: 912
Study 34000257 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 11558
Study 34000257 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 11558
Study 32703266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐pregnancy BMI (per 5‐unit increase)
Number of subjects: 1583
Study 32703266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐pregnancy overweight
Number of subjects: 1583
Study 32703266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐pregnancy obesity
Number of subjects: 1583
Study 32703266 — intervention group
Group type: COMPARATOR
Intervention: Excessive GWG vs. non-excessive GWG
Number of subjects: 1583
Study 32703266 — intervention group
Group type: EXPERIMENTAL
Intervention: GWG per 1 kg increase
Number of subjects: 1583
Study 36270464 — intervention group
Group type: EXPERIMENTAL
Intervention: transcranial random noise stimulation (tRNS)
Number of subjects: 64
Study 33453456 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1.5 g/6 h)
Number of subjects: 34
Study 33453456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 32130809 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir and rilpivirine (monthly intramuscular injections)
Number of subjects: 616
Study 32130809 — intervention group
Group type: COMPARATOR
Intervention: Oral therapy (standard antiretroviral therapy)
Number of subjects: 616
Study 35559498 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide (GC group)
Number of subjects: 8
Study 35559498 — intervention group
Group type: COMPARATOR
Intervention: Saline (PLA group)
Number of subjects: 8
Study 35000582 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey medicinal gel (unheated natural honey)
Number of subjects: 48
Study 35000582 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 48
Study 34048095 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment for 2 weeks
Number of subjects: 14
Study 34048095 — intervention group
Group type: COMPARATOR
Intervention: Healthy horses (control group)
Number of subjects: 14
Study 33045769 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV; tidal volume of 9‐10 mL/kg predicted body weight with no positive end‐expiratory pressure)
Number of subjects: 42
Study 33045769 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilation (PV; tidal volume of 6‐8 mL/kg predicted body weight and 5 cmH₂O PEEP)
Number of subjects: 42
Study 33045769 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilation (PV)
Number of subjects: 42
Study 33045769 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 42
Study 35818757 — intervention group
Group type: EXPERIMENTAL
Intervention: SARUS CPR hood
Number of subjects: 15
Study 35818757 — intervention group
Group type: COMPARATOR
Intervention: Standard equipment
Number of subjects: 15
Study 34663784 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine administration
Number of subjects: 0
Study 34663784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36451616 — intervention group
Group type: EXPERIMENTAL
Intervention: Active‐tDCS (N=20 with pain)
Number of subjects: 80
Study 36451616 — intervention group
Group type: COMPARATOR
Intervention: Sham‐tDCS (N=20 with pain)
Number of subjects: 80
Study 36451616 — intervention group
Group type: EXPERIMENTAL
Intervention: Active‐tDCS (N=20 without pain)
Number of subjects: 80
Study 36451616 — intervention group
Group type: COMPARATOR
Intervention: Sham‐tDCS (N=20 without pain)
Number of subjects: 80
Study 33857914 — intervention group
Group type: EXPERIMENTAL
Intervention: Qing-Chang-Hua-Shi granules (125 g/day)
Number of subjects: 119
Study 33857914 — intervention group
Group type: COMPARATOR
Intervention: Placebo (125 g/day)
Number of subjects: 119
Study 36272243 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel added to the interrupted microdose flare protocol
Number of subjects: 60
Study 36272243 — intervention group
Group type: COMPARATOR
Intervention: Conventional microdose flare protocol
Number of subjects: 60
Study 34619734 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin 1 g (group 1)
Number of subjects: 756
Study 34619734 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin 1 g with oral amoxicillin 2 g (group 2)
Number of subjects: 756
Study 34619734 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 3)
Number of subjects: 756